Brodalumab-An IL-17RA monoclonal antibody for psoriasis and psoriatic arthritis

Expert Opinion on Biological Therapy

Volumn 15, Issue 6, 2015, Pages 883-893

  Bauer, Erin ^a   Lucier, Jessica ^a   Furst, Daniel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmune disease; Brodalumab; IL 17 therapy; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

BRODALUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 17; PLACEBO; USTEKINUMAB; IL17RA PROTEIN, HUMAN; INTERLEUKIN 17 RECEPTOR; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ARTICLE; ASTHMA; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; FATIGUE; FEVER; HEADACHE; HUMAN; INFLAMMATORY BOWEL DISEASE; INJECTION SITE REACTION; NAUSEA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS, PSORIATIC; HUMANS; INTERLEUKIN-17; RECEPTORS, INTERLEUKIN-17;

EID: 84929899736     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1045410     Document Type: Article

References (45)

1. Langley RGB, Krueger GG, Griffiths CEM. Psoriatic arthritis and psoriasis: classification, clinical features, pathophysiology, immunology, genetics. Ann Rheum Dis 2005;64:18-23
2. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005;53(4):573
3. Kappelman MD, Rifas-shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohns disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5(12):1424-9
4. Akinbami LJ, Moorman JE, Bailey C, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. NCHS Data Brief 2012(94):1-8
5. Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity 2011;34(2):149-62
6. Chang SH, Dong C. Signaling of interleukin-17 family cytokines in immunity and inflammation. Cell Signal 2011;23(7):1069-75
7. Jin W, Dong C. IL-17 cytokines in immunity and inflammation. Emer Microbes Infect 2013;2:e60
8. Van den berg WB, Mcinnes IB. Th17 cells and IL-17 a: focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum 2013;43(2):158-70
9. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-82
10. Huang H, Kim HJ, Chang EJ, et al. IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ 2009;16:1332-43
11. Maddur S, et al. Review: Th17 cells. Am J Pathol 2012;181(1):03-44
12. Xiao S, Yosef N, Yang J, et al. Small-molecule RORgt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity 2014;40(4):477-89
13. Lowes MA, Kikuchi T, Fuentes-duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008;128(5):1207-11
14. Bluett J, Barton A. What have genomewide studies told us about psoriatic arthritis? Curr Rheumatol Rep 2012;14(4):364-8
15. Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Mol Cell Biochem 2012;359(1-2):419-29
16. Attur MG, Patel RN, Abramson SB, Amin AR. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 1997;40(6):1050-3
17. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003;52(1):65-70
18. Kawaguchi M, Kokubu F, Fujita J, et al. Role of interleukin-17F in asthma. Inflamm Allergy Drug Targets 2009;8(5):383-9
19. Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008; 205(5):1063-75
20. Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2013;72(6): 863-9
21. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-9
22. Salinger DH, Martin DA, Gibbs M. Exposure-response modeling of phase 1 data to inform phase 2 dose selection: a case study using AMG 827 in psoriasis. 40th Annual Meeting of the American College of Clinical Pharmacology; 11 -13 September 2011; Chicago, IL . Initial investigation of pharmacokinetics for brodalumab.
23. Martin DA, Churchill M, Flores-suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013;15(5):R164
24. Osamu N, Hirotaka N, Koji S, Kenji T. Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebocontrolled study. J Dermatol Sci 2014;75(3):201-4
25. Endres CJ, Salinger DH, Köck K, et al. Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies. J Clin Pharmacol 2014;54(11):1230-8
26. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366(13):1181-9
27. Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 2014;71(6):1183-90
28. Barber, J. Amgen, AstraZenecas brodalumab meets primary endpoints of third Phase III trial in moderate-Tosevere-plaque psoriasis. First Word Pharma, 2014. Web. 2015
29. Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014;370(24):2295-306
30. Pavelka K, Chon Y, Newmark R, et al. A randomized, double-blind, placebocontrolled, multiple-dose study to evaluate the safety, tolerability and efficacy of Brodalumab (AMG 827) in subjects with rheumatoid arthritis and an inadequate response to methotrexate. Arthrit Rheum 2012;64(10
31. Abstract at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting. 9 -14 November 2012; Washington, DC
32. Martin DA, Churchill M, Flores-suarez L, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther 2013;15(5):R164
33. Targan SR, Feagan BG, Vermeire S, et al. 2012 randomized, double-blind, placebocontrolled study to evaluate the safety, tolerability, and efficacy of AMG 827 in subjects with moderate to severe Crohns disease. Gastroenterology 2012;143
34. Busse WW, Holgate ST, Kerwin EM, et al. A randomized, double-blind, placebo-controlled, multiple-dose study to evaluate the safety, tolerability, and efficacy of brodalumab (AMG 827) in subjects with moderate to severe asthma. J Allergy Clin Immun 2013;131(2):AB230. . Trial suggestive that further studies of brodalumab may be warranted in asthma.
35. Strohal R, Puig L, Chouela E, et al. The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-To-severe psoriasis (the PRISTINE trial). J Dermatolog Treat 2013;24(3): 169-78
36. Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-To-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011;165(5):1109-17
37. Mcinnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382(9894):780-9
38. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264-72
39. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebocontrolled trial. Arthritis Rheum 2013;52:3279-89
40. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373(9664):633-40
41. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130(6): 478-86
42. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebocontrolled, phase III trial. Lancet 2009;374(9685):210-21
43. Keystone E, Heijde Dv, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-Two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study. Arthritis Rheum 2008;58(11):3319-29
44. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-Alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30(12):2563-71
45. Bongartz T, Sutton A, Sweeting MJ, et al. Anti-TNF antibody therpay in rheumatoid arthritis and the risk of serious infections and malignancies: A systemic review and meta-Analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295(19):2275-85